Released Nov 8, 2022, after the close
10-Q filed Nov 9, 2022, 40 days after period end · 0001162194-22-000098
Q3 2022 · 10-Q
Revenue$25.65M$25.65M −10.0% vs Q3 2021+36.6% vs Q2 2022
Net Income-$29.43M-$29.43M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.37-$0.37 N/M vs Q3 2021N/M vs Q2 2022
Gross Profit$9,220,000—
Operating Income-$29,027,000N/M
Operating Cash Flowderived-$24,611,000N/M
Free Cash Flowderived-$25,875,000N/M
Margins · derived
Gross margin36.0%
Operating margin-113.2%−44.4 pt vs Q3 2021
Net margin-114.7%−66.2 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $25.65M | $28.50M | $39.86M | $26.50M |
| Net Income | -$29.43M | -$13.84M | -$6.00M | -$12.89M |
| EPS Diluted | -$0.37 | -$0.18 | -$0.08 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR